GlaxoSmithKline (GSK) has appointed its consumer health leader, Emma Walmsley, to take over as CEO when Sir Andrew Witty retires next year. Walmsley has a background in marketing, and joined GSK ...

GlaxoSmithKline is under pressure from shareholders to rein in pay for its incoming chief executive, Emma Walmsley, according to reports. Walmsley is set to take over from Sir Andrew Witty when he ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

Walmsley, the only woman CEO of a major pharma company, told Fortune at the time that GSK was working on building its vaccine portfolio. That’s not the only avenue where GSK is growing.

GlaxoSmithKline (GSK) has named its current head of consumer healthcare, Emma Walmsley, as its next chief executive, replacing 'GSK lifer' Andrew Witty at the helm of Britain's biggest pharmaceuticals ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Emma Walmsley needs to convince shareholders she has the right plan. The boss of GlaxoSmithKline faces one of the biggest challenges of her career as she tries to convince shareholders in the ...

Pharmaceutical giant GlaxoSmithKline saw third-quarter sales ... This keeps it on track to hit its full-year targets as new boss Emma Walmsley refocuses its drugs range. Sales rose 4% to £7.8bn ...

Our speakers today are Emma Walmsley, Luke Miels, Deb Waterhouse, and Julie Brown, with Tony Wood and David Redfern joining for Q&A. Please ask only one to two questions, so that everyone has a ...

Drugs firm GSK (GlaxoSmithKline) has lifted its profits and sales growth targets for the year after a boost from cancer and ...

GlaxoSmithKline will combine its consumer ... and significant benefits to patients and consumers," said Emma Walmsley, chief executive of GSK. The Glaxo-Pfizer deal comes on a huge day for the ...

At the Financial Times (FT) Global Pharma and Biotech Summit in London on 6 November, GSK CEO Emma Walmsley addressed these concerns and underscored the critical role of the US in GSK’s operations.